• Physicians
  • By Specialty
  • By Name
  • By Language
• Medical Services
• Primary Care Centers
  • Centerville Health Center
  • Greenwood Health Center (Midvale)
  • Madsen Health Center (SLC)
  • Parkway Health Center (Orem)
  • Redstone Health Center (Park City)
  • Redwood Health Center (South SLC)
  • South Jordan Health Center
  • Sugar House Health Center
  • Stansbury Health Center (Tooele)
  • Urgent Care / After Hours
  • Westridge Health Center (West Valley City)
• Hospitals & Specialty Centers
  • University Hospital & Clinics
  • Cardiovascular Center
  • Clinical Neurosciences Center
  • Huntsman Cancer Hospital
  • Moran Eye Center
  • Rehabilitation Center
  • University Neuropsychiatric Institute
  • University Orthopaedic Center
  • Utah Diabetes Center
  • Other Specialty Centers

Clinical trials for diseases other than Psoriasis

People with shrimp allergies are sought in a trial to develop a vaccine for people allergic to the small shellfish. Allergy specialist Gerald J. Gleich, M.D., wants to find out if there is more than one type of sensitivity to shrimp and then test whether that sensitivity can be reduced when people are vaccinated with small pieces of the shrimp protein that causes allergy. Study participants, who will receive compensation, will be given skin tests and blood tests to check for sensitivity to shrimp and related foods, such as crab and lobster. People interested in participating in the study can call (801) 581-6465 for more information. 

Randomized placebo-controlled trial using pimecrolimus for the treatment of erosive oral lichen planus. Sponsor is U of Utah Deparment of Dermatology and Novartis Pharmaceuticals. Status-still enrolling. Contact Katherine Sebastian at 581-6465. Age> 18years. Biopsy confirmed oral erosive lichen planus. Duration of study is 12 weeks. Enrollment will close this fall

Pathogenesis of Dermatitis Herpetiformis. Sponsor University of Utah and Dermatology Foundation. Currently enrolling patients with known dermatitis herpetiformis. Study involves collecting a blood sample. Contact Katherine Sebastian at 581-6465.

EDEMA4 is a Phase 3, multicenter, double-blind, placebo-controlled study to further support the validity of the patient reported outcome and to confirm efficacy and safety of DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE). An open-label, repeat dosing study is available for all participants.

Study evaluating the importance of IgE antibodies in the blood of patients with bullous pemphigoid. We believe that these antibodies are important in producing the blistering skin lesions. Eliminating these antibodies may produce significant improvement in bullous pemphigoid. We will obtain blood and skin specimens from patients with bullous pemphigoid, dermatitis herpetiformis and pemphigus and study this blood in the laboratory to determine types of antibodies that may be responsible for disease in these patients. The study is sponsored by the Department of Veterans affairs and the University Of Utah Department Of Dermatology. Status: still enrolling. Contact John J. Zone M.D. Or Laurence J. Meyer Ph.D. M.D. At 801-581-6465. Duration: 1 time donation of specimens.

Icatibant JE 049 #2103 is a study evaluating Hereditary angioedema (HAE). Hereditary angioedema is an autosomal dominant disorder clinically characterized by recurrent and self-limiting episodes of edema of the skin, larynx, and gastriointestinal tract. This is a multi-site study which is no longer enrolling. For questions contact Gerald Gleich M.D. at 801-581-6465.

Please call 581-6465 for additional information.